KRAS and familial pancreatic carcinoma: To formally assess the role of GSL metabolism in KRAS oncogenesis, we treated multiple KRAS mutant pancreatic cancer cell lines and a non-transformed pancreatic epithelial cell strain with a UGCG inhibitor.